Quantcast
Last updated on April 17, 2014 at 17:30 EDT

Latest Venous thrombosis Stories

2014-02-19 23:30:15

http://www.DrugNews.net is the web’s premier source for prescription drug warnings, research, side effects and legal news. Visit the DrugNews Center today. New York, NY (PRWEB) February 19, 2014 The birth control safety center at DrugNews.net is alerting users of the contraceptives Yaz or Yasmin of new information on the site. Health experts in the United Kingdom recently ordered a warning for patients that the drugs may greatly increase the rate of blood clots*. At the same time, court...

2014-01-16 23:00:31

The DrugRisk Center is the largest source on the Web for information on prescription drug research, side effects and legal news. Visit http://www.DrugRisk.com Orlando, FL (PRWEB) January 16, 2014 The birth control safety advocates at DrugRisk.com are now offering help to patients who have taken Yaz or Yasmin with questions about settlements. This is in addition to information on the site about the latest research, warnings and legal news on contraceptives like Yaz that use the hormone...

2014-01-08 23:00:18

A NuvaRing lawsuit recently filed by Wright & Schulte alleges that a Florida woman developed deep vein thrombosis and pulmonary embolism due to her use of NuvaRing. Columbus, OH (PRWEB) January 08, 2014 Wright & Schulte is currently representing a woman from Cape Coral, Florida in a recently filed NuvaRing lawsuit (Case No. 2:13-cv-00721-SPC-DNF). This case, which was filed in the U.S. District Court of Ohio, contends that the plaintiff developed serious blood clotting disorders...

2014-01-08 12:30:25

Submission based on the two largest comparative phase 3 clinical trials of a novel oral anticoagulant in patients with non-valvular atrial fibrillation or symptomatic venous thromboembolism TOKYO and PARSIPPANY, N.J., Jan. 8, 2014 /PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the New Drug Application (NDA) for its investigational, oral, once-daily direct factor Xa-inhibitor SAVAYSA(TM) (edoxaban) Tablets has been submitted to the U.S. Food...

2014-01-07 23:00:15

The DrugRisk Center is the largest source on the Web for information on prescription drug research, side effects and legal news. Visit http://www.DrugRisk.com Chicago, IL (PRWEB) January 07, 2014 For 2014, the prescription drug safety advocates at DrugRisk.com have launched a new patient resource center for women who have taken the birth control pills Yaz or Yasmin. The site will offer the latest research, warnings and legal news on contraceptives like Yaz that use the hormone...

2014-01-07 12:28:27

Submission based on the two largest comparative phase 3 clinical trials of a novel oral anticoagulant in patients with non-valvular atrial fibrillation or symptomatic venous thromboembolism TOKYO and MUNICH, Jan. 7, 2014 /PRNewswire/ -- Daiichi Sankyo, Company Limited (hereafter, Daiichi Sankyo) today announced that the Marketing Authorization Application (MAA) for its investigational, oral, once-daily direct factor Xa-inhibitor edoxaban has been submitted to the European Medicines Agency...

2013-12-19 08:26:43

-- Submission based on the two largest comparative phase 3 clinical trials of a novel oral anticoagulant in patients with non-valvular atrial fibrillation or symptomatic venous thromboembolism TOKYO, Dec. 19, 2013 /PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has submitted a supplemental New Drug Application (NDA) for its oral, once-daily direct factor Xa-inhibitor LIXIANA(®) (Edoxaban Tosilate Hydrate) for review by the Japanese Ministry...

2013-12-17 08:28:51

RE-COVER II(TM) trial shows dabigatran non-inferior to warfarin in preventing recurrent DVT and/or PE and related death, with a reduction in major or clinically relevant non-major bleeding RIDGEFIELD, Conn., Dec. 17, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced results from the RE-COVER(TM) II study evaluating dabigatran compared to warfarin in patients diagnosed with acute deep vein thrombosis (DVT) and/or pulmonary embolism (PE). In this Phase III study,...

2013-12-11 08:30:15

$1.7 million award supports University of Michigan collaboration with GlycoMimetics, Inc. ANN ARBOR, Mich., Dec. 11, 2013 /PRNewswire-USNewswire/ --- The University of Michigan has been awarded $1.7 million to collaborate with GlycoMimetics, Inc., to study a new class of anticoagulants to help millions of Americans at risk or venous thromboembolic disease (VTE), a serious blood-clotting disorder. The National Heart Lung and Blood Institute is supporting the three-year clinical trial...

2013-12-09 08:29:05

- VTE patients with cancer treated with once-daily edoxaban had a numerically lower incidence of recurrent VTE and a 36% lower risk of clinically relevant bleeding compared to warfarin in a subgroup analysis of the phase 3 Hokusai-VTE study(1) NEW ORLEANS and TOKYO, Dec. 9, 2013 /PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced results of a prespecified subgroup analysis of 771 cancer patients enrolled in the phase 3 Hokusai-VTE study. Patients with...